Ikarian Capital, LLC Aeterna Zentaris Inc. Transaction History

Ikarian Capital, LLC

  • $573 Million
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2020

Nov 16, 2020
SELL
$0.34 - $0.55 $39,930 - $64,593
-117,443 Closed
0 $0
Q4 2019

Jan 31, 2020
BUY
$0.77 - $1.08 $90,431 - $126,838
117,443 New
117,443 $107,000

About Aeterna Zentaris Inc.

AEZS Quotes by TradingView
  • Ticker AEZS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 4,855,880
  • Market Cap $19.4M
  • Description
  • Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult grow...
More about AEZS
Track This Portfolio

Track Ikarian Capital, LLC Portfolio

Follow Ikarian Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ikarian Capital, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email